Professor Qingyuan Zhang: Treatment Strategies for HR+/HER2- Advanced Breast Cancer Patients After Progression on CDK4/6i+ET

Professor Qingyuan Zhang: Treatment Strategies for HR+/HER2- Advanced Breast Cancer Patients After Progression on CDK4/6i+ET

While CDK4/6 inhibitors plus endocrine therapy (ET) have become the standard first-line treatment for HR+/HER2- advanced breast cancer patients, there is currently no standardized recommendation for treatment strategies after progression on CDK4/6 inhibitors plus ET. At the "2024 National Breast Cancer Conference," "Oncology Frontier" had the privilege of inviting Professor Qingyuan Zhang from Harbin Medical University Cancer Hospital to discuss the factors to consider and the available treatment strategies for patients who have progressed on CDK4/6 inhibitors plus ET.
Professor Shaohua Zhang: “CSCO BC Guidelines” Updated, Evidence-Based, Leading Chinese Clinical Practice

Professor Shaohua Zhang: “CSCO BC Guidelines” Updated, Evidence-Based, Leading Chinese Clinical Practice

The "Chinese Society of Clinical Oncology (CSCO) Breast Cancer Diagnosis and Treatment Guidelines (2024 Edition)" ("CSCO BC Guidelines") have been updated again, incorporating richer evidence-based medicine from early to late stages, introducing more new treatment strategies and options. It has influenced the field of breast cancer treatment in China significantly. "Oncology Frontier" interviewed Professor Shaohua Zhang from The Fifth Medical Center of the People's Liberation Army General Hospital to discuss the highlights and clinical significance of the updated "CSCO BC Guidelines".
2024 National Breast Cancer Congress | Professor Yingying Xu: Reflections on Translational Research Based on Neoadjuvant Platforms

2024 National Breast Cancer Congress | Professor Yingying Xu: Reflections on Translational Research Based on Neoadjuvant Platforms

Currently, neoadjuvant therapy has become an optimized treatment modality for locally advanced and some early-stage breast cancers. It can optimize local surgery by downsizing tumors and provide efficacy and prognostic information to guide adjuvant therapy, thus improving survival. Moreover, it serves as an excellent platform for personalized treatment efficacy prediction and new drug development. Translational research based on neoadjuvant platforms has significant value in selecting benefiting populations, predicting effective regimens, and achieving personalized and precise treatments. At the "2024 National Breast Cancer Congress," Professor Yingying Xu from The First Affiliated Hospital of China Medical University delivered a speech titled "Reflections on Translational Research Based on Neoadjuvant Platforms," which we will introduce in this article.
EBMTChina’s Voice| Professor Tong Wu: Innovative Explorations in the Application of Hematopoietic Stem Cell Transplantation Technology

EBMTChina’s Voice| Professor Tong Wu: Innovative Explorations in the Application of Hematopoietic Stem Cell Transplantation Technology

The 50th European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting was held in Glasgow, UK, from April 14th to 17th, 2024. The conference focused on the latest developments in stem cell transplantation and cell therapy, pushing forward better clinical outcomes for patients with hematologic diseases and blood cancers. At this meeting, Dr. Gao's team presented six research findings, covering innovative explorations and practices in hematopoietic stem cell transplantation, as well as the combined application of CAR-T and hematopoietic stem cell transplantation. They shared advanced concepts and research findings, contributing China's wisdom to the global stage and sharing innovative results with the world. This article includes a translation and compilation of two posters from Professor Tong Wu’s team for the enjoyment of our readers.
Exclusive Interview | Academician Yuming Lu : The Application of Liquid Biopsy Based on Plasma DNA Fragmentomics in Early Cancer Screening

Exclusive Interview | Academician Yuming Lu : The Application of Liquid Biopsy Based on Plasma DNA Fragmentomics in Early Cancer Screening

Liquid biopsy is a cutting-edge technology that utilizes molecular biomarkers in human body fluids for analysis, thereby obtaining relevant disease information. In the era of precision medicine, liquid biopsy has become an indispensable tool in the field of tumor diagnosis and treatment. It has received extensive attention and research for its applications in early tumor screening, treatment plan selection, disease recurrence monitoring, and biopharmaceuticals. Notably, plasma free DNA fragmentomics, as an emerging technology in the field of liquid biopsy, is increasingly applied in the diagnosis of various cancers.
BISC 2024 | Professor Yunsong Yu: The Current Epidemic Situation and Challenges of CRO Infections in China

BISC 2024 | Professor Yunsong Yu: The Current Epidemic Situation and Challenges of CRO Infections in China

In recent years, the detection rate of carbapenem-resistant Gram-negative bacteria (CRO) in China has remained high, posing serious challenges to clinical treatments and patient outcomes. The limited therapeutic options have left many clinical needs unmet. At the recent Fourth National Conference on Bacterial and Fungal Infections organized by the Chinese Medical Association (BISC 2024), Professor Yunsong Yu from Zhejiang Provincial People's Hospital delivered a presentation titled "The Current Epidemic Situation and Challenges of Carbapenem-Resistant Organisms (CRO) Infections in China." Professor Yu detailed the prevalence and treatment status of CRO in China and explored the clinical challenges and strategies in depth.
Professor Rong Fan: Precision Screening for Liver Cancer Patients in China

Professor Rong Fan: Precision Screening for Liver Cancer Patients in China

Primary liver cancer is currently the fourth most common malignant tumor and the second leading cause of cancer death in China, posing a serious threat to the health and well-being of the population. Reducing the burden associated with liver cancer remains a major challenge in the fields of public health and chronic disease prevention in China. Optimizing screening strategies for liver cancer populations is an important ongoing focus and direction. On April 15, 2024, the National Health Commission released the "Primary Liver Cancer Diagnosis and Treatment Guidelines (2024 Edition)," recommending the aMAP, aMAP-2, and aMAP-2 Plus series of liver cancer risk scoring developed by the research team of Professor Jinlin Hou/Professor Rong Fan from Southern Medical University's Southern Hospital for screening and monitoring high-risk liver cancer populations. At the recent 2024 Greater Bay Area Hepatology Summit and the Conference on the Elimination of Viral Hepatitis, Professor Rong Fan delivered an outstanding report titled "Precision Screening for Liver Cancer Patients in China." Our publication has specially invited Professor Rong Fan to provide an in-depth discussion on this hot topic of concern.
Professor Chunrong Ju Provides a Comprehensive Overview of IFD Diagnosis and Treatment Strategies in SOT Recipients at BISC 2024

Professor Chunrong Ju Provides a Comprehensive Overview of IFD Diagnosis and Treatment Strategies in SOT Recipients at BISC 2024

Solid Organ Transplantation (SOT) is a crucial procedure for saving the lives of patients with end-stage organ failure. In recent years, the field of SOT has flourished in China, with significant improvements in the number of transplants and treatment outcomes. However, infections remain a critical factor affecting the survival and quality of life of SOT recipients. Among these, the incidence and mortality rates of invasive fungal diseases (IFD) are particularly high, especially among lung transplant recipients. At the recent 4th National Conference on Bacterial and Fungal Infections organized by the Chinese Medical Association (BISC 2024), the journal "Infection Medicine Today" had the opportunity to interview Professor Chunrong Ju from The First Affiliated Hospital of Guangzhou Medical University. Professor Ju shared her expert insights on the prevalence, current treatment landscape, and diagnostic challenges of IFD in SOT recipients, as well as discussed strategies for improving treatment outcomes through precision medicine.
Professor Yujie Wu: Standardized Flow Cytometry Detection of CLL-MRD | The 15th Experimental Diagnostic Hematology Conference of the Chinese Medical Association and the 1st Conference on Rare Blood Diseases

Professor Yujie Wu: Standardized Flow Cytometry Detection of CLL-MRD | The 15th Experimental Diagnostic Hematology Conference of the Chinese Medical Association and the 1st Conference on Rare Blood Diseases

As spring blossoms and nature revives, the 15th Experimental Diagnostic Hematology Conference and the 1st Conference on Rare Blood Diseases, hosted by the Chinese Medical Association, were grandly held in the city of Gusu on March 23-24, 2024. The conference invited renowned experts and scholars from the field of hematology both domestically and internationally to deliver enlightening academic presentations and engage in thematic discussions. The aim was to foster academic exchange and cooperation in the fields of experimental diagnostic hematology and rare blood diseases, to share the latest research findings, discuss industry trends, and collectively promote the prosperity of hematology in China. At the conference, Professor Yujie Wu from Jiangsu Provincial People's Hospital (The First Affiliated Hospital of Nanjing Medical University) delivered an excellent presentation titled "Standardized Flow Cytometry Detection of CLL-MRD," which is specially compiled here for our readers' enjoyment.

Dr. Jimmy Che-To LAI, two award winners, talks about the 2024 APASLAnnual Meeting

From March 27 to 31, 2024, the 33rd Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL 2024) was held in Kyoto, Japan. As a top international conference, this year's APASL annual meeting brings together a large number of the latest research progress. After the feast, the heat did not abate. In the multi-day academic feast, what important research, cutting-edge views have been released, and what novel news events have occurred, let us listen to Dr. Jimmy Che-To LAI of the Chinese University of Hong Kong, China, and once again feel the pulse of Asia in the field of liver disease.